In this Healio Video Perspective, Dilraj Grewal, MD, discusses an analysis of the VISTA and VIVID studies exploring the impact of baseline vision on visual outcomes and vision-related quality of life function in diabetic macular edema.
Grewal presented results from the post hoc analysis, which examined patients with DME who were treated with 2 mg aflibercept, at the Retina Society meeting.
“Patients with better baseline vision may achieve improved visual outcomes as well as vision-related quality of life for up to 2 years of treatment,” he said.